Filing Flows › Aclaris Therapeutics (ACRS) › Q3 2026 › vs Q2 2026
Aclaris Therapeutics (ACRS) Q3 2026 vs Q2 2026 (quarter over quarter)
Aclaris Therapeutics's revenue fell $148K (-9%) from $1.6M in Q2 2026 to $1.5M in Q3 2026. The biggest changes: Licensing −$92K (-7%); Contract research −$56K (-16%).
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Licensing | $1.2M | $1.3M | −$92K | -7% |
| Contract research | $300K | $356K | −$56K | -16% |
| Revenue | $1.5M | $1.6M | −$148K | -9% |
| Other income, net | $2.8M | $2.7M | $101K | +4% |
| Net loss | $18.5M | $21.5M | −$3.0M | -14% |
| Costs & expenses | $22.8M | $25.9M | −$3.0M | -12% |
| Operating costs | $22.8M | $25.9M | −$3.0M | -12% |
| Cost of revenue | $189K | $218K | −$29K | -13% |
| Research & development | $16.1M | $18.1M | −$2.0M | -11% |
| General & admin | $6.0M | $6.0M | −$10K | -0.2% |
| Other operating costs | $532K | $1.5M | −$1.0M | -65% |
| Operating cash sources | $27.2M | $22.6M | $4.6M | +20% |
| Depreciation & amortization | $100K | $107K | −$7K | -7% |
| Share-based compensation | $3.0M | $2.7M | $347K | +13% |
| Cash used in operations | $24.1M | $19.8M | $4.2M | +21% |
| Net loss absorbed | $18.5M | $21.5M | −$3.0M | -14% |
| Working capital & other | $8.7M | $1.1M | $7.6M | +675% |
Questions
How much did Aclaris Therapeutics's revenue grow quarter over quarter in Q3 2026?
Aclaris Therapeutics's revenue fell $148K (-9%) from $1.6M in Q2 2026 to $1.5M in Q3 2026.
What drove Aclaris Therapeutics's revenue change in Q3 2026?
Licensing −$92K (-7%); Contract research −$56K (-16%).